🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Biomarkers Impact Evaluation on the Post-transplant Immune Response After Allografting of Hematopoietic Stem Cells

RecruitingNAAges 18 Years - anyAllCentre Hospitalier Universitaire de Saint Etienne
NCT04517656 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Chemotherapy or targeted therapy are usually used to treat hematological pathologies. Despite of medical improvement, some of these pathologies present drug resistances, or high risk of relapse. Hematopoietic stem cell (HSC) transplantation remain the gold standard of consolidation, to maintain a durable response. In this situation, allograft with hematopoietic stem cells donor aims at producing Graft-versus-Tumor effect, by producing a new immune system, reproducing anti-tumoral immunity. However, all hemopathies do not have the same sensibility. Nowadays, mechanisms underlying this phenomenon remain poorly understood. Indeed, few data precisely document the expression of immunological checkpoints and other biomarkers in the context of allogeneic HSC transplantation, particularly their impact on post-transplant outcome.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adult patient, over 18 years of age, suffering from a malignant hemopathy (without exception), * Patient for whom an allogeneic hematopoietic stem cell transplant from a related or unrelated donor is indicated, * Signed informed consent, * Patient covered by a social security scheme. Exclusion Criteria: * Allogeneic hematopoietic stem cell transplantation from cord blood or haplo-identical transplant, * Allogeneic transplant with post-transplant cyclophosphamide treatment, * Allograft with sequential conditioning.
💊

What it tests

  • Blood samples
📍

Where

1 site
CHU de Saint-Etienne
Saint-Etienne, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy